Endothelin converting-enzyme-1 mRNA expression in human cardiovascular disease

H. Bohnemeier; Y. M. Pinto; F. Horkay; M. Tóth; A. Juhász-Nagy; H. D. Orzechowski; M. Böhm; M. Paul

doi:https://doi.org/10.3109/10641969809053222

Endothelin converting-enzyme-1 mRNA expression in human cardiovascular disease

H. Bohnemeier, Y. M. Pinto, F. Horkay, M. Tóth, A. Juhász-Nagy, H. D. Orzechowski, M. Böhm, M. Paul

Other Departments

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Abstract

Endothelin-1 converting-enzyme (ECE-1) cleaves the precursor, big-endothelin-1, to the active peptide endothelin-1. The aim of this study was to investigate whether ECE-1 mRNA expression is modified in human cardiovascular disease. Tissue samples from the left human atrium were analyzed for ECE-1 expression and related to different clinical parameters. A quantitative PCR assay (qPCR) with competitive and non-competitive standards was established. The ECE-1 measurements were normalized by a GAPDH qPCR. Patients who suffered from a myocardial infarction had elevated ECE-1 levels when compared to controls (5.81+/-0.76 vs. 3.20+/-0.51 fg ECE-1, ng GAPDH, p <0.05). Drug treatment with the beta-blocker metoprolol was associated with a decreased ECE-1 expression level (3.90+/-0.58 vs. 5.81+/-0.76 fg ECE-1, ng GAPDH, p <0.1). We conclude that the expression of ECE-1 is altered in the atrial tissue depending on the physiological status of the heart. This suggests a differential role of ECE-1 in cardiovascular diseases

Original language	English
Pages (from-to)	417-437
Journal	Clinical and experimental hypertension (New York, N.Y.
Volume	20
Issue number	4
DOIs	https://doi.org/10.3109/10641969809053222
Publication status	Published - 1998

Access to Document

https://doi.org/10.3109/10641969809053222

Cite this

@article{c8a01ff6eac14aad870755520d9dd66b,

title = "Endothelin converting-enzyme-1 mRNA expression in human cardiovascular disease",

abstract = "Endothelin-1 converting-enzyme (ECE-1) cleaves the precursor, big-endothelin-1, to the active peptide endothelin-1. The aim of this study was to investigate whether ECE-1 mRNA expression is modified in human cardiovascular disease. Tissue samples from the left human atrium were analyzed for ECE-1 expression and related to different clinical parameters. A quantitative PCR assay (qPCR) with competitive and non-competitive standards was established. The ECE-1 measurements were normalized by a GAPDH qPCR. Patients who suffered from a myocardial infarction had elevated ECE-1 levels when compared to controls (5.81+/-0.76 vs. 3.20+/-0.51 fg ECE-1, ng GAPDH, p <0.05). Drug treatment with the beta-blocker metoprolol was associated with a decreased ECE-1 expression level (3.90+/-0.58 vs. 5.81+/-0.76 fg ECE-1, ng GAPDH, p <0.1). We conclude that the expression of ECE-1 is altered in the atrial tissue depending on the physiological status of the heart. This suggests a differential role of ECE-1 in cardiovascular diseases",

author = "H. Bohnemeier and Pinto, {Y. M.} and F. Horkay and M. T{\'o}th and A. Juh{\'a}sz-Nagy and Orzechowski, {H. D.} and M. B{\"o}hm and M. Paul",

year = "1998",

doi = "https://doi.org/10.3109/10641969809053222",

language = "English",

volume = "20",

pages = "417--437",

journal = "Clinical and experimental hypertension (New York, N.Y.",

issn = "1064-1963",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Endothelin converting-enzyme-1 mRNA expression in human cardiovascular disease

AU - Bohnemeier, H.

AU - Pinto, Y. M.

AU - Horkay, F.

AU - Tóth, M.

AU - Juhász-Nagy, A.

AU - Orzechowski, H. D.

AU - Böhm, M.

AU - Paul, M.

PY - 1998

Y1 - 1998

N2 - Endothelin-1 converting-enzyme (ECE-1) cleaves the precursor, big-endothelin-1, to the active peptide endothelin-1. The aim of this study was to investigate whether ECE-1 mRNA expression is modified in human cardiovascular disease. Tissue samples from the left human atrium were analyzed for ECE-1 expression and related to different clinical parameters. A quantitative PCR assay (qPCR) with competitive and non-competitive standards was established. The ECE-1 measurements were normalized by a GAPDH qPCR. Patients who suffered from a myocardial infarction had elevated ECE-1 levels when compared to controls (5.81+/-0.76 vs. 3.20+/-0.51 fg ECE-1, ng GAPDH, p <0.05). Drug treatment with the beta-blocker metoprolol was associated with a decreased ECE-1 expression level (3.90+/-0.58 vs. 5.81+/-0.76 fg ECE-1, ng GAPDH, p <0.1). We conclude that the expression of ECE-1 is altered in the atrial tissue depending on the physiological status of the heart. This suggests a differential role of ECE-1 in cardiovascular diseases

AB - Endothelin-1 converting-enzyme (ECE-1) cleaves the precursor, big-endothelin-1, to the active peptide endothelin-1. The aim of this study was to investigate whether ECE-1 mRNA expression is modified in human cardiovascular disease. Tissue samples from the left human atrium were analyzed for ECE-1 expression and related to different clinical parameters. A quantitative PCR assay (qPCR) with competitive and non-competitive standards was established. The ECE-1 measurements were normalized by a GAPDH qPCR. Patients who suffered from a myocardial infarction had elevated ECE-1 levels when compared to controls (5.81+/-0.76 vs. 3.20+/-0.51 fg ECE-1, ng GAPDH, p <0.05). Drug treatment with the beta-blocker metoprolol was associated with a decreased ECE-1 expression level (3.90+/-0.58 vs. 5.81+/-0.76 fg ECE-1, ng GAPDH, p <0.1). We conclude that the expression of ECE-1 is altered in the atrial tissue depending on the physiological status of the heart. This suggests a differential role of ECE-1 in cardiovascular diseases

U2 - https://doi.org/10.3109/10641969809053222

DO - https://doi.org/10.3109/10641969809053222

M3 - Article

C2 - 9607404

SN - 1064-1963

VL - 20

SP - 417

EP - 437

JO - Clinical and experimental hypertension (New York, N.Y.

JF - Clinical and experimental hypertension (New York, N.Y.

IS - 4

ER -